Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $12.3333.

EVAX has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Evaxion A/S in a research note on Monday, October 20th. Lake Street Capital upped their target price on shares of Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Edward Jones began coverage on shares of Evaxion A/S in a research note on Thursday, October 30th. They set a “buy” rating and a $10.00 price target for the company. Jones Trading raised Evaxion A/S to a “strong-buy” rating in a report on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 14th.

Evaxion A/S Trading Up 4.3%

EVAX opened at $5.13 on Friday. The stock’s 50 day simple moving average is $5.69 and its 200-day simple moving average is $4.17. The stock has a market cap of $42.78 million, a PE ratio of -13.15 and a beta of 0.28. Evaxion A/S has a 1 year low of $1.20 and a 1 year high of $12.15.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evaxion A/S stock. Merck & Co. Inc. grew its position in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) by 123.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,214,126 shares of the company’s stock after purchasing an additional 671,847 shares during the period. Evaxion A/S comprises approximately 1.4% of Merck & Co. Inc.’s holdings, making the stock its 6th biggest holding. Merck & Co. Inc. owned about 86.54% of Evaxion A/S worth $2,246,000 as of its most recent filing with the SEC. Institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.